Metformin increases AMP-activated protein-kinase activity in skeletal muscle of subjects with type 2 diabetes

Diabetes

Volumn 51, Issue 7, 2002, Pages 2074-2081

  Musi, Nicolas ^a   Hirshman, Michael F ^a   Nygren, Jonas ^b   Svanfeldt, Monika ^c   Bavenholm, Peter ^c   Rooyackers, Olav ^c   Zhou, Gaochao ^d   Williamson, Joanne M ^d   Ljunqvist, Olle ^b,c   Efendic, Suad ^c   Moller, David E ^d   Thorell, Anders ^b   Goodyear, Laurie J ^a,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ERSTA HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d MERCK RESEARCH LABORATORIES   (United States)

^e JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENOSINE TRIPHOSPHATE; CREATINE PHOSPHATE; GLYCOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; PROTEIN KINASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG MECHANISM; ENERGY; ENZYME ACTIVATION; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SKELETAL MUSCLE;

EID: 0036299982     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.7.2074     Document Type: Article

References (62)

1. Metformin: A review of its metabolic effects
2. Effects of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes
3. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
4. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
5. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
6. Mechanism by which metformin reduces glucose production in type 2 diabetes
7. Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes
8. Troglitazone, but not metformin, restores insulin-stimulated phosphoinositide 3-kinase activity in skeletal muscle of type 2 diabetic subjects
9. The AMP-activated/SNF1 protein kinase subfamily: Metabolic sensors of the eukaryotic cell?
10. Dealing with energy demand: The AMP-activated protein kinase
11. Mammalian AMP-activated protein kinase subfamily
12. The AMP-activated protein kinase-fuel gauge of the mammalian cell?
13. Dual regulation of the AMP-activated protein kinase provides a novel mechanism for the control of creatine kinase in skeletal muscle
14. AMP-activated protein kinase, a metabolic master switch: Possible roles in type 2 diabetes
15. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle
16. Evidence for 5′ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport
17. Effect of AMPK activation on muscle glucose metabolism in conscious rats
18. Chronic activation of 5′-AMP-activated protein kinase increases GLUT4, hexokinase, and glycogen in muscle
19. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle
20. Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin
21. Chronic treatment with 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside increases insulin-stimulated glucose uptake and GLUT4 translocation in rat skeletal muscles in a fiber type-specific manner
22. Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes
23. Hypoglycaemic effect of AICAriboside in mice
24. 5-Aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase
25. Role of AMP-activated protein kinase in mechanism of metformin action
26. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
27. Use of glucose oxidase and O-dianisidin in determinations of blood and urinary glucose
28. Rapid micromeasurement of lactate in whole blood
29. AMP-activated protein kinase (AMPK) is activated in muscle of subjects with type 2 diabetes during exercise
30. Tissue distribution of the AMP-activated protein kinase, and lack of activation by cyclic-AMP-dependent protein kinase, studied using a specific and sensitive peptide assay
31. Insulin activation of acetyl-CoA carboxylase accompanied by inhibition of the 5′-AMP-activated protein kinase
32. Preoperative oral carbohydrate treatment attenuates immediate postoperative insulin resistance
33. Modeling error and apparent isotope discrimination confound estimation of endogenous glucose production during euglycemic glucose clamps
34. Site of insulin resistance after surgery: The contribution of hypocaloric nutrition and bed rest
35. Trimethylsilyl-O-methyloxime derivatives for the measurement of [6,62H2]-D-glucose-enriched plasma samples by GCMS
36. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase
37. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I
38. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain
39. Effect of metformin treatment on insulin action in diabetic rats: In vivo and in vitro correlations
40. Postreceptor effect of metformin on insulin action in mice
41. Glucose transport in human skeletal muscle cells in culture: Stimulation by insulin and metformin
42. AMP-activated protein kinase activity and glucose uptake in rat skeletal muscle
43. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats
44. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients
45. Effect of metformin on glucose metabolism in mouse soleus muscle
46. Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM
47. Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells
48. In vivo metformin treatment ameliorates insulin resistance: Evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes
49. Biguanide treatment increases the number of insulin-receptor sites on human erythrocytes
50. Effect of metformin on insulin-stimulated tyrosine kinase activity of erythrocytes from obese women with normal glucose tolerance
51. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients
52. Mechanism of action of metformin: Insulin receptor and postreceptor effects in vitro and in vivo
53. The antidiabetic drug metformin elevates receptor tyrosine kinase activity and inositol 1,4,5-trisphosphate mass in Xenopus oocytes
54. Stimulation of the intracellular portion of the human insulin receptor by the antidiabetic drug metformin
55. Inhibition of hepatic gluconeogenesis by metformin: Synergism with insulin
56. Accumulation of metformin by tissues of the normal and diabetic mouse
57. Postexercise recovery of skeletal muscle malonyl-CoA, acetyl-CoA carboxylase, and AMP-activated protein kinase
58. Exercise induces isoform-specific increase in 5′AMP-activated protein kinase activity in human skeletal muscle
59. Isoform specific and exercise intensity-dependent activation of 5′-AMP-activated protein kinase in human skeletal muscle
60. Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle
61. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2